Advertisement
Screener

RECURSION PHARMACEUTICALS, INC. (RXRX) Total Long-Term Debt

2.8 / 5 stars · 68/120 Roast Me

RECURSION PHARMACEUTICALS, INC. Total Long-Term Debt

RECURSION PHARMACEUTICALS, INC. (RXRX) had Total Long-Term Debt of $723.00 thousand as of 2021-12-31, per its 10-K filed 2022-03-23.

Discontinued › Balance Sheet › Liabilities

us-gaap:LongTermDebt · last filed 2022-03-23

  • 2021-12-31: Long-term Debt $723.00K.
  • 2021-09-30: Long-term Debt $744.00K.
  • 2021-06-30: Long-term Debt $12.66M.
  • 2021-03-31: Long-term Debt $12.68M.
Period endLong-term Debt
2021-12-31$723.00K
10-K · filed 2022-03-23
2021-09-30$744.00K
10-Q · filed 2021-11-10
2021-06-30$12.66M
10-Q · filed 2021-08-13
2021-03-31$12.68M
10-Q · filed 2021-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Vericel Corp (VCEL)United States$2.011B93.97
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Greenland Mines Ltd (GRML)United States$2.362B
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Immunocore Holdings plc (IMCR)$1.613B-90.43
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51